Related Experiment Video

Updated: Jun 24, 2026

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
06:38

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

Recent advances in molecular targeted therapy for metastatic renal cell carcinoma

Yoichi Mizutani1

  • 1Department of Urology, Kyoto Prefectural University of Medicine, Kyoto, Japan. ymizutan@koto.kpu-m.ac.jp

International Journal of Urology : Official Journal of the Japanese Urological Association
|March 21, 2009
PubMed

Insights

Advanced renal cell carcinoma (RCC) is resistant to traditional treatments. New molecular targeted therapies offer promising options for metastatic RCC, with potential for combination treatments in the future.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Advanced renal cell carcinoma (RCC) exhibits resistance to conventional chemotherapy and radiotherapy.
  • Current immunotherapy for RCC shows limited response rates, necessitating novel therapeutic strategies.

Purpose of the Study:

  • To review the emerging molecular targeted therapies for advanced renal cell carcinoma.
  • To discuss the potential of these agents and combination therapies in clinical practice.

Main Methods:

  • Review of recent scientific literature on molecular mechanisms and targeted agents in RCC.
  • Analysis of therapeutic efficacy and future prospects of identified molecular targeted drugs.

Main Results:

  • Several molecular targeted agents, including bevacizumab, sorafenib, sunitinib, axitinib, temsirolimus, and everolimus, are identified as promising for metastatic RCC.
  • These targeted therapies are expected to see wider clinical application soon.

Conclusions:

  • Molecular targeted therapy represents a significant advancement in treating advanced renal cell carcinoma.
  • Future treatment paradigms may involve combination therapies, integrating molecular targeted agents with immunotherapy.

More Related Videos

Modeling Spontaneous Metastatic Renal Cell Carcinoma (mRCC) in Mice Following Nephrectomy11:27

Modeling Spontaneous Metastatic Renal Cell Carcinoma (mRCC) in Mice Following Nephrectomy

Published on: April 29, 2014

The Use of Reverse Phase Protein Arrays (RPPA) to Explore Protein Expression Variation within Individual Renal Cell Cancers12:22

The Use of Reverse Phase Protein Arrays (RPPA) to Explore Protein Expression Variation within Individual Renal Cell Cancers

Published on: January 22, 2013

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Metastasis02:30

Metastasis

Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...